SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Sangamo Therapeutics, Inc. – ‘10-K’ for 12/31/23 – ‘EX-101.SCH’

On:  Wednesday, 3/13/24, at 7:47am ET   ·   For:  12/31/23   ·   Accession #:  1628280-24-10788   ·   File #:  0-30171

Previous ‘10-K’:  ‘10-K’ on 2/23/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   34 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/13/24  Sangamo Therapeutics, Inc.        10-K       12/31/23   96:41M                                    Workiva Inc Wde… FA01/FA

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.33M 
 2: EX-4.1      Instrument Defining the Rights of Security Holders  HTML     41K 
 3: EX-10.24    Material Contract                                   HTML     45K 
 4: EX-10.35    Material Contract                                   HTML     33K 
 5: EX-10.36    Material Contract                                   HTML     33K 
 6: EX-21.1     Subsidiaries List                                   HTML     27K 
 7: EX-23.1     Consent of Expert or Counsel                        HTML     29K 
 8: EX-31.1     Certification -- §302 - SOA'02                      HTML     32K 
 9: EX-31.2     Certification -- §302 - SOA'02                      HTML     32K 
10: EX-32.1     Certification -- §906 - SOA'02                      HTML     31K 
16: R1          Cover                                               HTML     94K 
17: R2          Audit Information                                   HTML     33K 
18: R3          Consolidated Balance Sheets                         HTML    140K 
19: R4          Consolidated Balance Sheets (Parenthetical)         HTML     48K 
20: R5          Consolidated Statements of Operations               HTML    108K 
21: R6          Consolidated Statements of Comprehensive Loss       HTML     60K 
22: R7          Consolidated Statements of Stockholders? Equity     HTML    111K 
23: R8          Consolidated Statements of Cash Flows               HTML    137K 
24: R9          Organization, Basis of Presentation and Summary of  HTML    114K 
                Significant Accounting Policies                                  
25: R10         Fair Value Measurements                             HTML     88K 
26: R11         Cash Equivalents and Marketable Securities          HTML     92K 
27: R12         Major Customers, Partnerships and Strategic         HTML    129K 
                Alliances                                                        
28: R13         Acquisition of Sangamo France                       HTML     34K 
29: R14         Impairment of Goodwill, Indefinite-Lived            HTML     42K 
                Intangible Assets and Other Long-Lived Assets                    
30: R15         Other Balance Sheet Details                         HTML     65K 
31: R16         Commitments and Contingencies                       HTML     55K 
32: R17         Stockholders' Equity                                HTML     65K 
33: R18         Stock-Based Compensation                            HTML     56K 
34: R19         Restructuring Charges                               HTML     42K 
35: R20         Employee Benefit Plan                               HTML     34K 
36: R21         Income Taxes                                        HTML    120K 
37: R22         Subsequent Event                                    HTML     32K 
38: R23         Organization, Basis of Presentation and Summary of  HTML    129K 
                Significant Accounting Policies (Policies)                       
39: R24         Organization, Basis of Presentation and Summary of  HTML     72K 
                Significant Accounting Policies (Tables)                         
40: R25         Fair Value Measurements (Tables)                    HTML     85K 
41: R26         Cash Equivalents and Marketable Securities          HTML     88K 
                (Tables)                                                         
42: R27         Major Customers, Partnerships and Strategic         HTML     67K 
                Alliances (Tables)                                               
43: R28         Other Balance Sheet Details (Tables)                HTML     68K 
44: R29         Commitments and Contingencies (Tables)              HTML     48K 
45: R30         Stockholders' Equity (Tables)                       HTML     53K 
46: R31         Stock-Based Compensation (Tables)                   HTML     57K 
47: R32         Restructuring Charges (Tables)                      HTML     35K 
48: R33         Income Taxes (Tables)                               HTML    121K 
49: R34         ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF  HTML     64K 
                SIGNIFICANT ACCOUNTING POLICIES - Narrative                      
                (Details)                                                        
50: R35         ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF  HTML     42K 
                SIGNIFICANT ACCOUNTING POLICIES - Schedule of                    
                Revenues from Collaboration and Licensing                        
                Agreements (Details)                                             
51: R36         ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF  HTML     42K 
                SIGNIFICANT ACCOUNTING POLICIES - Schedule of                    
                Percentage of Accounts Receivable by Collaboration               
                Partners (Details)                                               
52: R37         ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF  HTML     37K 
                SIGNIFICANT ACCOUNTING POLICIES - Schedule of                    
                Cash, Cash Equivalents and Restricted Cash                       
                (Details)                                                        
53: R38         Fair Value Measurements (Details)                   HTML    103K 
54: R39         CASH EQUIVALENTS AND MARKETABLE SECURITIES -        HTML     82K 
                Schedule of Cash Equivalents and Marketable                      
                Securities (Details)                                             
55: R40         CASH EQUIVALENTS AND MARKETABLE SECURITIES -        HTML     36K 
                Schedule of Fair Value of Marketable Securities by               
                Contractual Maturity (Details)                                   
56: R41         CASH EQUIVALENTS AND MARKETABLE SECURITIES -        HTML     37K 
                Narrative (Details)                                              
57: R42         MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC         HTML     85K 
                ALLIANCES - Pfizer Inc. (Narrative) (Details)                    
58: R43         MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC         HTML     85K 
                ALLIANCES - Kite Pharma, Inc. (Narrative)                        
                (Details)                                                        
59: R44         MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC         HTML     57K 
                ALLIANCES - Schedule of Revenues Recognized under                
                Agreement (Details)                                              
60: R45         MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC         HTML     52K 
                ALLIANCES - Novartis Institutes for BioMedical                   
                Research, Inc. (Narrative) (Details)                             
61: R46         MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC         HTML     84K 
                ALLIANCES - Biogen MA, Inc. (Narrative) (Details)                
62: R47         MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC         HTML     83K 
                ALLIANCES - Sanofi S.A. (Narrative) (Details)                    
63: R48         MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC         HTML     47K 
                ALLIANCES - California Institute for Regenerative                
                Medicine (Narrative) (Details)                                   
64: R49         MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC         HTML     60K 
                ALLIANCES - Agreement with Sigma-Aldrich                         
                Corporation (Narrative) (Details)                                
65: R50         Acquisition of Sangamo France (Details)             HTML     45K 
66: R51         Impairment of Goodwill, Indefinite-Lived            HTML     53K 
                Intangible Assets and Other Long-Lived Assets                    
                (Details)                                                        
67: R52         OTHER BALANCE SHEET DETAILS - Schedule of Property  HTML     48K 
                and Equipment, Net (Details)                                     
68: R53         OTHER BALANCE SHEET DETAILS - Narrative (Details)   HTML     46K 
69: R54         OTHER BALANCE SHEET DETAILS - Schedule of           HTML     50K 
                Intangible Assets and Goodwill (Details)                         
70: R55         OTHER BALANCE SHEET DETAILS - Schedule of Other     HTML     44K 
                Accrued Liabilities (Details)                                    
71: R56         COMMITMENTS AND CONTINGENCIES - Narrative           HTML     89K 
                (Details)                                                        
72: R57         COMMITMENTS AND CONTINGENCIES - Schedule of         HTML     35K 
                Components of Operating Leases (Details)                         
73: R58         COMMITMENTS AND CONTINGENCIES - Schedule of Future  HTML     56K 
                Minimum Payments under Lease Obligations (Details)               
74: R59         STOCKHOLDERS' EQUITY - Narrative (Details)          HTML    142K 
75: R60         STOCKHOLDERS' EQUITY - Schedule of Stock Option     HTML     68K 
                Activity (Details)                                               
76: R61         STOCKHOLDERS' EQUITY - Schedule of Restricted       HTML     46K 
                Stock Unit Activity (Details)                                    
77: R62         STOCK-BASED COMPENSATION - Schedule of Stock-Based  HTML     36K 
                Compensation Expense (Details)                                   
78: R63         STOCK-BASED COMPENSATION - Narrative (Details)      HTML     55K 
79: R64         STOCK-BASED COMPENSATION - Schedule of Assumptions  HTML     52K 
                used for Estimating Fair Value of Employee Stock                 
                Options (Details)                                                
80: R65         STOCK-BASED COMPENSATION - Schedule of Assumptions  HTML     52K 
                used for Estimating the Fair Value of the ESPP                   
                Purchase Rights (Details)                                        
81: R66         RESTRUCTURING CHARGES - Narrative (Details)         HTML     88K 
82: R67         RESTRUCTURING CHARGES - Schedule of Accrued         HTML     38K 
                Restructuring Costs (Details)                                    
83: R68         Employee Benefit Plan (Details)                     HTML     34K 
84: R69         INCOME TAXES - Schedule of Domestic and Foreign     HTML     38K 
                Components of Loss Before Income Taxes (Details)                 
85: R70         INCOME TAXES - Schedule of Income Tax Expense       HTML     54K 
                (Benefit) (Details)                                              
86: R71         INCOME TAXES - Schedule of Difference Between       HTML     54K 
                Income Tax Expense (Benefit) and Federal Statutory               
                Income Tax Rate to Loss Before Income Taxes                      
                (Details)                                                        
87: R72         INCOME TAXES - Schedule of Deferred Tax Assets and  HTML     67K 
                Liabilities (Details)                                            
88: R73         INCOME TAXES - Schedule of Deferred Tax Assets and  HTML     37K 
                Liabilities Based on Tax Jurisdictions (Details)                 
89: R74         INCOME TAXES - Narrative (Details)                  HTML     59K 
90: R75         INCOME TAXES - Schedule of Unrecognized Tax         HTML     38K 
                Benefits (Details)                                               
91: R76         Subsequent Event (Details)                          HTML     50K 
93: XML         IDEA XML File -- Filing Summary                      XML    182K 
96: XML         XBRL Instance -- sgmo-20231231_htm                   XML   2.35M 
92: EXCEL       IDEA Workbook of Financial Report Info              XLSX    204K 
12: EX-101.CAL  XBRL Calculations -- sgmo-20231231_cal               XML    246K 
13: EX-101.DEF  XBRL Definitions -- sgmo-20231231_def                XML    894K 
14: EX-101.LAB  XBRL Labels -- sgmo-20231231_lab                     XML   1.87M 
15: EX-101.PRE  XBRL Presentations -- sgmo-20231231_pre              XML   1.35M 
11: EX-101.SCH  XBRL Schema -- sgmo-20231231                         XSD    223K 
94: JSON        XBRL Instance as JSON Data -- MetaLinks              542±   860K 
95: ZIP         XBRL Zipped Folder -- 0001628280-24-010788-xbrl      Zip  12.43M

‘EX-101.SCH’   —   XBRL Schema — sgmo-20231231

This Exhibit is an XBRL File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- XBRL Document Created with the Workiva Platform -->
<!-- Copyright 2024 Workiva -->
<!-- r:9100d2f2-69f4-4def-a66d-ae91ccb97111,g:2e734f81-f65c-4bf8-a13b-4c3fd0383cc2 -->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20231231">
<xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
<xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
<xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
<xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
<xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xs:annotation>
<xs:appinfo>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="Cover" roleURI="http://www.sangamo.com/role/Cover">
<link:definition> 0000001 - Document - Cover </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="AuditInformation" roleURI="http://www.sangamo.com/role/AuditInformation">
<link:definition> 0000002 - Document - Audit Information </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.sangamo.com/role/CONSOLIDATEDBALANCESHEETS">
<link:definition> 0000003 - Statement - CONSOLIDATED BALANCE SHEETS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.sangamo.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
<link:definition> 0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.sangamo.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
<link:definition> 0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.sangamo.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
<link:definition> 0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.sangamo.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
<link:definition> 0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.sangamo.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
<link:definition> 0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
<link:definition> 0000009 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS">
<link:definition> 0000010 - Disclosure - FAIR VALUE MEASUREMENTS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIES" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES">
<link:definition> 0000011 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES">
<link:definition> 0000012 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ACQUISITIONOFSANGAMOFRANCE" roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOFRANCE">
<link:definition> 0000013 - Disclosure - ACQUISITION OF SANGAMO FRANCE </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="IMPAIRMENTOFGOODWILLINDEFINITELIVEDINTANGIBLEASSETSANDOTHERLONGLIVEDASSETS" roleURI="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLINDEFINITELIVEDINTANGIBLEASSETSANDOTHERLONGLIVEDASSETS">
<link:definition> 0000014 - Disclosure - IMPAIRMENT OF GOODWILL, INDEFINITE-LIVED INTANGIBLE ASSETS AND OTHER LONG-LIVED ASSETS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="OTHERBALANCESHEETDETAILS" roleURI="http://www.sangamo.com/role/OTHERBALANCESHEETDETAILS">
<link:definition> 0000015 - Disclosure - OTHER BALANCE SHEET DETAILS </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIES">
<link:definition> 0000016 - Disclosure - COMMITMENTS AND CONTINGENCIES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY">
<link:definition> 0000017 - Disclosure - STOCKHOLDERS' EQUITY </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION">
<link:definition> 0000018 - Disclosure - STOCK-BASED COMPENSATION </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="RESTRUCTURINGCHARGES" roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGES">
<link:definition> 0000019 - Disclosure - RESTRUCTURING CHARGES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="EMPLOYEEBENEFITPLAN" roleURI="http://www.sangamo.com/role/EMPLOYEEBENEFITPLAN">
<link:definition> 0000020 - Disclosure - EMPLOYEE BENEFIT PLAN </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="INCOMETAXES" roleURI="http://www.sangamo.com/role/INCOMETAXES">
<link:definition> 0000021 - Disclosure - INCOME TAXES </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="SUBSEQUENTEVENT" roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENT">
<link:definition> 0000022 - Disclosure - SUBSEQUENT EVENT </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
<link:definition> 9954471 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
<link:definition> 9954472 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables">
<link:definition> 9954473 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESTables" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables">
<link:definition> 9954474 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables">
<link:definition> 9954475 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="OTHERBALANCESHEETDETAILSTables" roleURI="http://www.sangamo.com/role/OTHERBALANCESHEETDETAILSTables">
<link:definition> 9954476 - Disclosure - OTHER BALANCE SHEET DETAILS (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="COMMITMENTSANDCONTINGENCIESTables" roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESTables">
<link:definition> 9954477 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYTables">
<link:definition> 9954478 - Disclosure - STOCKHOLDERS' EQUITY (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables">
<link:definition> 9954479 - Disclosure - STOCK-BASED COMPENSATION (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="RESTRUCTURINGCHARGESTables" roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESTables">
<link:definition> 9954480 - Disclosure - RESTRUCTURING CHARGES (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="INCOMETAXESTables" roleURI="http://www.sangamo.com/role/INCOMETAXESTables">
<link:definition> 9954481 - Disclosure - INCOME TAXES (Tables) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
<link:definition> 9954482 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofRevenuesfromCollaborationandLicensingAgreementsDetails" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofRevenuesfromCollaborationandLicensingAgreementsDetails">
<link:definition> 9954483 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Revenues from Collaboration and Licensing Agreements (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofAccountsReceivablebyCollaborationPartnersDetails" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofPercentageofAccountsReceivablebyCollaborationPartnersDetails">
<link:definition> 9954484 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Percentage of Accounts Receivable by Collaboration Partners (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashCashEquivalentsandRestrictedCashDetails">
<link:definition> 9954485 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="FAIRVALUEMEASUREMENTSDetails" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSDetails">
<link:definition> 9954486 - Disclosure - FAIR VALUE MEASUREMENTS (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESScheduleofCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESScheduleofCashEquivalentsandMarketableSecuritiesDetails">
<link:definition> 9954487 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Schedule of Cash Equivalents and Marketable Securities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESScheduleofFairValueofMarketableSecuritiesbyContractualMaturityDetails" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESScheduleofFairValueofMarketableSecuritiesbyContractualMaturityDetails">
<link:definition> 9954488 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Schedule of Fair Value of Marketable Securities by Contractual Maturity (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESNarrativeDetails">
<link:definition> 9954489 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Narrative (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncNarrativeDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESPfizerIncNarrativeDetails">
<link:definition> 9954490 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncNarrativeDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESKitePharmaIncNarrativeDetails">
<link:definition> 9954491 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESScheduleofRevenuesRecognizedunderAgreementDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESScheduleofRevenuesRecognizedunderAgreementDetails">
<link:definition> 9954492 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Schedule of Revenues Recognized under Agreement (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncNarrativeDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESNovartisInstitutesforBioMedicalResearchIncNarrativeDetails">
<link:definition> 9954493 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Novartis Institutes for BioMedical Research, Inc. (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncNarrativeDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESBiogenMAIncNarrativeDetails">
<link:definition> 9954494 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSANarrativeDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESSanofiSANarrativeDetails">
<link:definition> 9954495 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Sanofi S.A. (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESCaliforniaInstituteforRegenerativeMedicineNarrativeDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESCaliforniaInstituteforRegenerativeMedicineNarrativeDetails">
<link:definition> 9954496 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - California Institute for Regenerative Medicine (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAgreementwithSigmaAldrichCorporationNarrativeDetails" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAgreementwithSigmaAldrichCorporationNarrativeDetails">
<link:definition> 9954497 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Agreement with Sigma-Aldrich Corporation (Narrative) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="ACQUISITIONOFSANGAMOFRANCEDetails" roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOFRANCEDetails">
<link:definition> 9954498 - Disclosure - ACQUISITION OF SANGAMO FRANCE (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="IMPAIRMENTOFGOODWILLINDEFINITELIVEDINTANGIBLEASSETSANDOTHERLONGLIVEDASSETSDetails" roleURI="http://www.sangamo.com/role/IMPAIRMENTOFGOODWILLINDEFINITELIVEDINTANGIBLEASSETSANDOTHERLONGLIVEDASSETSDetails">
<link:definition> 9954499 - Disclosure - IMPAIRMENT OF GOODWILL, INDEFINITE-LIVED INTANGIBLE ASSETS AND OTHER LONG-LIVED ASSETS (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="OTHERBALANCESHEETDETAILSScheduleofPropertyandEquipmentNetDetails" roleURI="http://www.sangamo.com/role/OTHERBALANCESHEETDETAILSScheduleofPropertyandEquipmentNetDetails">
<link:definition> 9954500 - Disclosure - OTHER BALANCE SHEET DETAILS - Schedule of Property and Equipment, Net (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="OTHERBALANCESHEETDETAILSNarrativeDetails" roleURI="http://www.sangamo.com/role/OTHERBALANCESHEETDETAILSNarrativeDetails">
<link:definition> 9954501 - Disclosure - OTHER BALANCE SHEET DETAILS - Narrative (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="OTHERBALANCESHEETDETAILSScheduleofIntangibleAssetsandGoodwillDetails" roleURI="http://www.sangamo.com/role/OTHERBALANCESHEETDETAILSScheduleofIntangibleAssetsandGoodwillDetails">
<link:definition> 9954502 - Disclosure - OTHER BALANCE SHEET DETAILS - Schedule of Intangible Assets and Goodwill (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="OTHERBALANCESHEETDETAILSScheduleofOtherAccruedLiabilitiesDetails" roleURI="http://www.sangamo.com/role/OTHERBALANCESHEETDETAILSScheduleofOtherAccruedLiabilitiesDetails">
<link:definition> 9954503 - Disclosure - OTHER BALANCE SHEET DETAILS - Schedule of Other Accrued Liabilities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
<link:definition> 9954504 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="COMMITMENTSANDCONTINGENCIESScheduleofComponentsofOperatingLeasesDetails" roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESScheduleofComponentsofOperatingLeasesDetails">
<link:definition> 9954505 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Components of Operating Leases (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumPaymentsunderLeaseObligationsDetails" roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumPaymentsunderLeaseObligationsDetails">
<link:definition> 9954506 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Payments under Lease Obligations (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumPaymentsunderLeaseObligationsDetails_1" roleURI="http://www.sangamo.com/role/COMMITMENTSANDCONTINGENCIESScheduleofFutureMinimumPaymentsunderLeaseObligationsDetails_1">
<link:definition> 9954506 - Disclosure - COMMITMENTS AND CONTINGENCIES - Schedule of Future Minimum Payments under Lease Obligations (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
<link:definition> 9954507 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYScheduleofStockOptionActivityDetails">
<link:definition> 9954508 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Stock Option Activity (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="STOCKHOLDERSEQUITYScheduleofRestrictedStockUnitActivityDetails" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYScheduleofRestrictedStockUnitActivityDetails">
<link:definition> 9954509 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Restricted Stock Unit Activity (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails">
<link:definition> 9954510 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
<link:definition> 9954511 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="STOCKBASEDCOMPENSATIONScheduleofAssumptionsusedforEstimatingFairValueofEmployeeStockOptionsDetails" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsusedforEstimatingFairValueofEmployeeStockOptionsDetails">
<link:definition> 9954512 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Assumptions used for Estimating Fair Value of Employee Stock Options (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="STOCKBASEDCOMPENSATIONScheduleofAssumptionsusedforEstimatingtheFairValueoftheESPPPurchaseRightsDetails" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsusedforEstimatingtheFairValueoftheESPPPurchaseRightsDetails">
<link:definition> 9954513 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Assumptions used for Estimating the Fair Value of the ESPP Purchase Rights (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="RESTRUCTURINGCHARGESNarrativeDetails" roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESNarrativeDetails">
<link:definition> 9954514 - Disclosure - RESTRUCTURING CHARGES - Narrative (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="RESTRUCTURINGCHARGESScheduleofAccruedRestructuringCostsDetails" roleURI="http://www.sangamo.com/role/RESTRUCTURINGCHARGESScheduleofAccruedRestructuringCostsDetails">
<link:definition> 9954515 - Disclosure - RESTRUCTURING CHARGES - Schedule of Accrued Restructuring Costs (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="EMPLOYEEBENEFITPLANDetails" roleURI="http://www.sangamo.com/role/EMPLOYEEBENEFITPLANDetails">
<link:definition> 9954516 - Disclosure - EMPLOYEE BENEFIT PLAN (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="INCOMETAXESScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails" roleURI="http://www.sangamo.com/role/INCOMETAXESScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails">
<link:definition> 9954517 - Disclosure - INCOME TAXES - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="INCOMETAXESScheduleofIncomeTaxExpenseBenefitDetails" roleURI="http://www.sangamo.com/role/INCOMETAXESScheduleofIncomeTaxExpenseBenefitDetails">
<link:definition> 9954518 - Disclosure - INCOME TAXES - Schedule of Income Tax Expense (Benefit) (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="INCOMETAXESScheduleofDifferenceBetweenIncomeTaxExpenseBenefitandFederalStatutoryIncomeTaxRatetoLossBeforeIncomeTaxesDetails" roleURI="http://www.sangamo.com/role/INCOMETAXESScheduleofDifferenceBetweenIncomeTaxExpenseBenefitandFederalStatutoryIncomeTaxRatetoLossBeforeIncomeTaxesDetails">
<link:definition> 9954519 - Disclosure - INCOME TAXES - Schedule of Difference Between Income Tax Expense (Benefit) and Federal Statutory Income Tax Rate to Loss Before Income Taxes (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.sangamo.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesDetails">
<link:definition> 9954520 - Disclosure - INCOME TAXES - Schedule of Deferred Tax Assets and Liabilities (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesBasedonTaxJurisdictionsDetails" roleURI="http://www.sangamo.com/role/INCOMETAXESScheduleofDeferredTaxAssetsandLiabilitiesBasedonTaxJurisdictionsDetails">
<link:definition> 9954521 - Disclosure - INCOME TAXES - Schedule of Deferred Tax Assets and Liabilities Based on Tax Jurisdictions (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.sangamo.com/role/INCOMETAXESNarrativeDetails">
<link:definition> 9954522 - Disclosure - INCOME TAXES - Narrative (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="INCOMETAXESScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.sangamo.com/role/INCOMETAXESScheduleofUnrecognizedTaxBenefitsDetails">
<link:definition> 9954523 - Disclosure - INCOME TAXES - Schedule of Unrecognized Tax Benefits (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
<link:roleType id="SUBSEQUENTEVENTDetails" roleURI="http://www.sangamo.com/role/SUBSEQUENTEVENTDetails">
<link:definition> 9954524 - Disclosure - SUBSEQUENT EVENT (Details) </link:definition>
<link:usedOn> link:presentationLink </link:usedOn>
<link:usedOn> link:calculationLink </link:usedOn>
<link:usedOn> link:definitionLink </link:usedOn>
</link:roleType>
</xs:appinfo>
</xs:annotation>
<xs:element id="sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_ExpiresInAugust2031Member" abstract="true" name="ExpiresInAugust2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment" abstract="false" name="ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_PfizerC9ORF72Member" abstract="true" name="PfizerC9ORF72Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_FullTimeEmployeesMember" abstract="true" name="FullTimeEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="sgmo_ChangeInAgreementEstimateSeptember2021Member" abstract="true" name="ChangeInAgreementEstimateSeptember2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="sgmo_GrantFundingAmount" abstract="false" name="GrantFundingAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" abstract="true" name="SharePurchaseAgreementAndTenderOfferAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" abstract="false" name="IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_RevenueNumberOfRemainingPerformanceObligations" abstract="false" name="RevenueNumberOfRemainingPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_RevenueRemainingPerformanceObligationRenewalPeriod" abstract="false" name="RevenueRemainingPerformanceObligationRenewalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="sgmo_AgreementTerminationTerm" abstract="false" name="AgreementTerminationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="sgmo_SaleOfStockIncreaseToAggregateOfferingPrice" abstract="false" name="SaleOfStockIncreaseToAggregateOfferingPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_FranceRestructuringPlanMember" abstract="true" name="FranceRestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationFixedConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_StockOfferingProgramMaximumValue" abstract="false" name="StockOfferingProgramMaximumValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecurities" abstract="false" name="CashEquivalentsAndAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
<xs:element id="sgmo_LeaseholdImprovementsAndConstructionInProgressMember" abstract="true" name="LeaseholdImprovementsAndConstructionInProgressMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="sgmo_OfficeAndLaboratoryMember" abstract="true" name="OfficeAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_IncreaseDecreaseInEarningsPerShareBasic" abstract="false" name="IncreaseDecreaseInEarningsPerShareBasic" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
<xs:element id="sgmo_IncreaseDecreaseInEarningsPerShareDiluted" abstract="false" name="IncreaseDecreaseInEarningsPerShareDiluted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
<xs:element id="sgmo_LesseeOperatingLeaseAmount" abstract="false" name="LesseeOperatingLeaseAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
<xs:element id="sgmo_EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationReductionInDeferredTaxLiabilitiesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_Restated2018StockIncentivePlanMember" abstract="true" name="Restated2018StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_ChangeInAgreementEstimateMarchAndSeptember2023Member" abstract="true" name="ChangeInAgreementEstimateMarchAndSeptember2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="sgmo_MilestoneAchievementMember" abstract="true" name="MilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_SangamoFranceMember" abstract="true" name="SangamoFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" abstract="false" name="EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
<xs:element id="sgmo_TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense" abstract="false" name="TerminationAndTransitionAgreementIncreaseDecreaseInResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" abstract="false" name="CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="sgmo_CollaborativeArrangementLicenseFee" abstract="false" name="CollaborativeArrangementLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
<xs:element id="sgmo_EffectiveIncomeTaxReconciliationTransferPricingSettlementAmount" abstract="false" name="EffectiveIncomeTaxReconciliationTransferPricingSettlementAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_ExpiresInAugust2026Member" abstract="true" name="ExpiresInAugust2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
<xs:element id="sgmo_ValbonneFranceMember" abstract="true" name="ValbonneFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" abstract="false" name="NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="sgmo_IntangibleAssetsExcludingGoodwillRollForward" abstract="true" name="IntangibleAssetsExcludingGoodwillRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
<xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
<xs:element id="sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" abstract="false" name="CollaborationAgreementNumberOfAdditionalProductTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="sgmo_NovartisInstitutesForBioMedicalResearchIncMember" abstract="true" name="NovartisInstitutesForBioMedicalResearchIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_SaleOfStockOutstandingAmountAvailable" abstract="false" name="SaleOfStockOutstandingAmountAvailable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentIncreaseDecrease" abstract="false" name="DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrentIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_ResearchServicesPeriod" abstract="false" name="ResearchServicesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="sgmo_LesseeTenantImprovementAllowanceWithinContraLeaseLiability" abstract="false" name="LesseeTenantImprovementAllowanceWithinContraLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_ManufacturingEquipmentMember" abstract="true" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_CollaborativeAgreementMilestoneDomain" abstract="true" name="CollaborativeAgreementMilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_SeparateUpfrontFee" abstract="false" name="SeparateUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent" abstract="false" name="IncreaseDecreaseInNetIncomeLossAttributableToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_PfizerSB525Member" abstract="true" name="PfizerSB525Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_GovernmentIncentivesTaxCreditRefundableResearchAmountRecognized" abstract="false" name="GovernmentIncentivesTaxCreditRefundableResearchAmountRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" abstract="false" name="CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod" abstract="false" name="RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="sgmo_EffectiveIncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" abstract="false" name="EffectiveIncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty" abstract="false" name="CollaborationAgreementNumberOfSelectedProductTargetsByCounterparty" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="sgmo_CollaborativeArrangementResearchServiceFees" abstract="false" name="CollaborativeArrangementResearchServiceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_RichmondCaliforniaMember" abstract="true" name="RichmondCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" abstract="false" name="ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_SBFiveTwoFiveMember" abstract="true" name="SBFiveTwoFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="sgmo_CollaborativeAgreementMilestoneAxis" abstract="true" name="CollaborativeAgreementMilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
<xs:element id="sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate" abstract="false" name="ResearchAndDevelopmentArrangementExpensesReimbursableAfterSpecifiedDate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" abstract="true" name="RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_CollaborativeAgreementPercentOfInitialRecognition" abstract="false" name="CollaborativeAgreementPercentOfInitialRecognition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
<xs:element id="sgmo_AchievementOfCommercialMilestonesMember" abstract="true" name="AchievementOfCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" abstract="false" name="SaleOfStockExcessConsiderationReceivedOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_AprilRestructuringPlanMember" abstract="true" name="AprilRestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="sgmo_CollaborationAgreementEquityIssued" abstract="false" name="CollaborationAgreementEquityIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_OtherLicensingAgreementsMember" abstract="true" name="OtherLicensingAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="sgmo_CollaborativeArrangementTransactionPrice" abstract="false" name="CollaborativeArrangementTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_SBFiveTwoFiveAndOtherProductsMember" abstract="true" name="SBFiveTwoFiveAndOtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_AccruedResearchAndDevelopmentExpenses" abstract="false" name="AccruedResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_NovemberRestructuringPlanMember" abstract="true" name="NovemberRestructuringPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" abstract="false" name="CustomerContractLiabilityMilestonePaymentEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate" abstract="false" name="ResearchAndDevelopmentArrangementExpensesReimbursableThroughSpecifiedDate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_CNineORFSevenTwoMember" abstract="true" name="CNineORFSevenTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_CommonStockExchangeRatio" abstract="false" name="CommonStockExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
<xs:element id="sgmo_TenantImprovementAllowanceWithinContraLeaseLiability" abstract="false" name="TenantImprovementAllowanceWithinContraLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_LonzaNetherlandsBVMember" abstract="true" name="LonzaNetherlandsBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_LicenseObligations" abstract="false" name="LicenseObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" abstract="true" name="CaliforniaInstituteForRegenerativeMedicineAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" abstract="false" name="CollaborativeArrangementEstimatedReimbursableServiceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_SanofiSAMember" abstract="true" name="SanofiSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_CollaborationAndLicenseAgreementMember" abstract="true" name="CollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_November2021ThroughAugust2031Member" abstract="true" name="November2021ThroughAugust2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="sgmo_AtTheMarketOfferingAgreementMember" abstract="true" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_ResearchAndOfficeSpaceMember" abstract="true" name="ResearchAndOfficeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_StockPurchaseAgreementMember" abstract="true" name="StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_ContractedEmployeesMember" abstract="true" name="ContractedEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" abstract="false" name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" abstract="false" name="BusinessAcquisitionNumberOfFreeSharesHeldByHolders" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
<xs:element id="sgmo_SigmaAldrichCorporationMember" abstract="true" name="SigmaAldrichCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_PurchasePlanOfferingPeriod" abstract="false" name="PurchasePlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="sgmo_ExtendedResearchTermOfAgreement" abstract="false" name="ExtendedResearchTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="sgmo_MilestoneThreeMember" abstract="true" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember" abstract="true" name="FurnitureFixturesAndLaboratoryAndManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
<xs:element id="sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
<xs:element id="sgmo_ReducedRoyaltyRate" abstract="false" name="ReducedRoyaltyRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
<xs:element id="sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" abstract="false" name="ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
<xs:element id="sgmo_InitialResearchTermOfAgreement" abstract="false" name="InitialResearchTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" abstract="false" name="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
<xs:element id="sgmo_USGovernmentSponsoredAgencyBondMember" abstract="true" name="USGovernmentSponsoredAgencyBondMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_AccountsReceivableFromCollaborationAgreementsCostReimbursementsConcentrationRiskMember" abstract="true" name="AccountsReceivableFromCollaborationAgreementsCostReimbursementsConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
<xs:element id="sgmo_NumberOfOptionsToExtendInitialResearchTerm" abstract="false" name="NumberOfOptionsToExtendInitialResearchTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="sgmo_PfizerMember" abstract="true" name="PfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" abstract="false" name="StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
<xs:element id="sgmo_MilestonePaymentsReceived" abstract="false" name="MilestonePaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" abstract="false" name="CollaborativeArrangementNumberOfMilestonesAchieved" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="sgmo_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
<xs:element id="sgmo_BrisbaneCaliforniaMember" abstract="true" name="BrisbaneCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_AdjustmentOfAwardLiability" abstract="false" name="AdjustmentOfAwardLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_MilestoneRevenueReceivable" abstract="false" name="MilestoneRevenueReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" abstract="true" name="AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_ReimbursementTenantImprovementAllowance" abstract="false" name="ReimbursementTenantImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_PurchasePlanPurchasePeriod" abstract="false" name="PurchasePlanPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
<xs:element id="sgmo_TwoThousandEighteenStockIncentivePlanMember" abstract="true" name="TwoThousandEighteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_BiogenMAIncMember" abstract="true" name="BiogenMAIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedInceptionToDatePercent" abstract="false" name="RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedInceptionToDatePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
<xs:element id="sgmo_JefferiesLLCMember" abstract="true" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_NumberOfResearchProgram" abstract="false" name="NumberOfResearchProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
<xs:element id="sgmo_KitePharmaIncMember" abstract="true" name="KitePharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
<xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
<xs:element id="sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" abstract="false" name="BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
<xs:element id="sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" abstract="false" name="ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
<xs:element id="sgmo_SpecifiedStockholderOwnershipPercentage" abstract="false" name="SpecifiedStockholderOwnershipPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
<xs:element id="sgmo_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
<xs:element id="sgmo_GovernmentIncentivesTaxCreditRefundableResearchAmount" abstract="false" name="GovernmentIncentivesTaxCreditRefundableResearchAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/25/24  Sangamo Therapeutics, Inc.        424B5                  1:3M                                     Donnelley … Solutions/FA

33 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/01/23  Sangamo Therapeutics, Inc.        10-Q        9/30/23   59:13M                                    Workiva Inc Wde… FA01/FA
 6/02/23  Sangamo Therapeutics, Inc.        8-K:5       6/01/23   14:12M                                    Workiva Inc Wde… FA01/FA
 3/07/23  Sangamo Therapeutics, Inc.        8-K:8,9     3/07/23   12:711K                                   Workiva Inc Wde… FA01/FA
 2/23/23  Sangamo Therapeutics, Inc.        10-K       12/31/22   87:116M                                   Workiva Inc Wde… FA01/FA
12/23/22  Sangamo Therapeutics, Inc.        8-K:1,9    12/23/22   12:699K                                   Workiva Inc Wde… FA01/FA
12/19/22  Sangamo Therapeutics, Inc.        8-K:5,9    12/15/22   11:7.4M                                   Workiva Inc Wde… FA01/FA
11/03/22  Sangamo Therapeutics, Inc.        10-Q        9/30/22   53:11M                                    Workiva Inc Wde… FA01/FA
 2/24/22  Sangamo Therapeutics, Inc.        10-K       12/31/21   94:51M                                    Workiva Inc Wde… FA01/FA
11/04/21  Sangamo Therapeutics, Inc.        10-Q        9/30/21   66:7.7M                                   Workiva Inc Wde… FA01/FA
 8/05/21  Sangamo Therapeutics, Inc.        10-Q        6/30/21   60:7.1M                                   Workiva Inc Wde… FA01/FA
 5/05/21  Sangamo Therapeutics, Inc.        S-3ASR      5/05/21    8:1.1M                                   Donnelley … Solutions/FA
 5/04/21  Sangamo Therapeutics, Inc.        10-Q        3/31/21   61:10M                                    Workiva Inc Wde… FA01/FA
11/04/20  Sangamo Therapeutics, Inc.        10-Q        9/30/20   59:8.4M                                   Workiva Inc Wde… FA01/FA
10/15/20  Sangamo Therapeutics, Inc.        S-8        10/15/20    4:143K                                   Donnelley … Solutions/FA
 8/05/20  Sangamo Therapeutics, Inc.        10-Q        6/30/20   63:10M                                    Workiva Inc Wde… FA01/FA
 5/11/20  Sangamo Therapeutics, Inc.        10-Q        3/31/20   61:43M                                    Workiva Inc Wde… FA01/FA
 2/28/20  Sangamo Therapeutics, Inc.        10-K       12/31/19   94:13M                                    Workiva Inc Wde… FA01/FA
11/06/19  Sangamo Therapeutics, Inc.        10-Q        9/30/19   60:7.9M                                   Workiva Inc Wde… FA01/FA
 5/08/19  Sangamo Therapeutics, Inc.        10-Q        3/31/19   57:7.3M                                   ActiveDisclosure/FA
 3/01/19  Sangamo Therapeutics, Inc.        10-K       12/31/18  103:14M                                    ActiveDisclosure/FA
11/06/18  Sangamo Therapeutics, Inc.        8-K:2,9    11/01/18    3:160K                                   Donnelley … Solutions/FA
 8/08/18  Sangamo Therapeutics, Inc.        10-Q        6/30/18   51:6.3M                                   ActiveDisclosure/FA
 7/23/18  Sangamo Therapeutics, Inc.        8-K:1,8,9   7/20/18    4:286K                                   Donnelley … Solutions/FA
 6/15/18  Sangamo Therapeutics, Inc.        8-K:5,9     6/11/18    9:507K                                   ActiveDisclosure/FA
 5/10/18  Sangamo Therapeutics, Inc.        10-Q        3/31/18   52:5.9M                                   ActiveDisclosure/FA
 3/01/18  Sangamo Therapeutics, Inc.        10-K       12/31/17   87:14M                                    ActiveDisclosure/FA
 1/06/17  Sangamo Therapeutics, Inc.        8-K:5,9     1/05/17    4:725K                                   Donnelley … Solutions/FA
 8/04/16  Sangamo Therapeutics, Inc.        10-Q        6/30/16   46:5M                                     ActiveDisclosure/FA
10/30/15  Sangamo Therapeutics, Inc.        10-Q        9/30/15   51:5.8M                                   ActiveDisclosure/FA
11/04/13  Sangamo Therapeutics, Inc.        10-Q        9/30/13   43:3.1M                                   Donnelley … Solutions/FA
 6/14/13  Sangamo Therapeutics, Inc.        8-K:5,9     6/12/13    7:198K                                   Donnelley … Solutions/FA
 2/23/05  Sangamo Therapeutics, Inc.        10-K       12/31/04    6:822K                                   Bowne - San Francisco/FA
 2/24/00  Sangamo Therapeutics, Inc.        S-1/A                 12:691K                                   Bowne - San Francisco/FA
↑Top
Filing Submission 0001628280-24-010788   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Thu., May 16, 12:21:37.3am ET